Portugal

Portugal sits in a relatively permissive personal-use drug policy environment, but classic psychedelics remain controlled medicines/substances rather than broadly accessible treatments. The practical picture is therefore narrow: decriminalisation reduces criminal penalties for possession for personal use, while clinical access depends on authorised medicines, regulated research, or carefully supervised private medical pathways.

Ask Blossom about this country

Data updated June 16, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inPortugal.

1
Portugal's policy stance is best described as decriminalised personal possession plus continued medicinal and criminal controls, not general legal access.
2
The clearest recent access signal is for esketamine in hospital care, which suggests the regulatory system can absorb psychedelic-adjacent medicines when they are authorised and evaluated for reimbursement.
3
Psilocybin activity is present but still research-led; the country page should be framed around trials and institutions rather than routine treatment access.
4
The palliative/distress signal is notable because it aligns with Blossom's active linked trial and suggests a small but coherent clinical niche rather than a broad ecosystem.
5
Publicly visible institutional activity is concentrated in Lisbon-based academic and hospital settings, with additional research capacity in Coimbra and Porto.

Research and Access Snapshot

Blossom currently tracks 3 psychedelic clinical trials connected to Portugal, including 1 active study.

Active trials: 1
Total trials: 3
Stakeholders: 5
Events: 1

Top Compounds

Psilocybin(2)
Esketamine(1)

Active Trial Preview

View all trials →

Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)Recruiting - II

Medical Access

Portugal has a decriminalised approach to personal drug possession (Law 30/2000) while maintaining statutory control over most classic psychedelics under the national drug schedules (Decree-Law n.o 15/93). Licensed pharmaceutical psychedelics have begun to enter regulated medical pathways (notably esketamine/Spravato, with Infarmed public-funding evaluation decisions in 2025), while other compounds remain available only within regulated clinical research or, in practice, via private/off-label clinic programmes subject to medical oversight and no routine...

View trials→View stakeholders→View events→Open access guide→

Are psychedelics legal in Portugal? Portugal decriminalised possession and use for personal use under Law 30/2000, but that is not legal retail or over-the-counter access, and controlled substances remain regulated. The esketamine spray Spravato received a public-financing deferment decision in May 2025 for hospital use in treatment-resistant major depression, supporting a narrow regulated medical pathway. By contrast, psilocybin and other classical psychedelics still appear confined to clinical research or highly controlled specialist use, and the exact picture for private or off-label programmes is not fully clear from public sources. Blossom tracks the regulatory picture; this is general information, not legal advice, and the law can change.

Regulatory Status

Portugal decriminalised possession and use for personal use under Law 30/2000, but that does not amount to legal retail or over-the-counter access, and controlled substances remain regulated under Decree-Law 15/93 and subsequent amendments. Recent INFARMED material shows esketamine (Spravato) received a public-financing deferment decision on 7 May 2025 for hospital use in treatment-resistant major depression, which supports a narrow, regulated medical pathway; by contrast, psilocybin and other classic psychedelics still appear confined to clinical research or highly controlled specialist use, with the exact patient-access picture for private/off-label programmes not fully clear from public sources.